Dr. Azoulay’s research program is in cancer pharmacoepidemiology. This program aims to provide much needed information on the long-term effects of commonly-prescribed drugs on the incidence of cancer, as well as to assess the safety of cancer treatments in the real-world setting. Over the years, Dr. Azoulay developed a strong interest on the potential effects of anti-diabetic drugs on the development of cancer. Examples include studies assessing the association between pioglitazone (a drug belonging to the thiazolidinedione class) and the risk of bladder cancer, and more recently, the association between newer antidiabetic agents (such as incretin-based drugs) and their association with pancreatic and breast cancer. With respect to the safety of cancer treatments, he has been particularly interested in the pleiotropic effects of androgen deprivation therapy, a common treatment used in advanced prostate cancer. His research program is funded by a Foundation Scheme Grant from the Canadian Institutes of Health Research.
Hicks BM, Yin H, Yu OH, Pollak MN, Platt RW, Azoulay L. Glucagon-like peptide-1 analogues and risk of breast cancer in women with type 2 diabetes: population based cohort study using the UK Clinical Practice Research Datalink. BMJ 2016 355:i5340.
Tuccori M, Filion KB, Yin H, Yu OH, Platt RW, Azoulay L. Pioglitazone use and bladder cancer risk: a population-based cohort study. BMJ 2016 30;352:i1541.
Filion KB, Azoulay L, Platt RW, Dahl M, Dormuth CR, Clemens KK, Hu N, Paterson JM, Targownik L, Turin TC, Udell JA, Ernst P, and the CNODES Investigators. A multi-center observational study of incretin-based drugs and the risk of heart failure. N Engl J Med 2016 24;374(12):1145-54.
Azoulay L, Filion KB, Platt RW, Dahl M, Dormuth CR, Clemens KK, Durand M, Juurlink DN, Targownik LE, Turin TC, Paterson JM, Ernst P; Canadian Network for Observational Drug Effect Studies Investigators. Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study. BMJ 2016 17;352:i581.